D-0361-2022 Class II Terminated
FDA drug recall D-0361-2022 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Oct 22, 2021 and is designated Class II. Reason for recall: Failed Tablet/Capsule Specifications: Out of Specification results for particle Size Distribution and Bulk Density of the Active Pharmaceutical Ingredient. The recall status is terminated (terminated Apr 6, 2023). Affected quantity: 696 Bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 12, 2022
- Initiation Date
- Oct 22, 2021
- Termination Date
- Apr 6, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 696 Bottles
Product description
Pregabalin Capsules, 50 mg, 100 count bottle, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Ltd., Survey No. 259/15 Dadra-396 191, (U.T. of D & NH), India, NDC 47335-687-88.
Reason for recall
Failed Tablet/Capsule Specifications: Out of Specification results for particle Size Distribution and Bulk Density of the Active Pharmaceutical Ingredient.
Distribution pattern
Nationwide in the USA
Code information
Lot number: DNC0432A, expiration 01/2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0361-2022
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026